Integral Health Asset Management LLC Buys Shares of 1,500,000 Esperion Therapeutics, Inc. $ESPR

Integral Health Asset Management LLC acquired a new stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 1,500,000 shares of the biopharmaceutical company’s stock, valued at approximately $3,975,000.

Other institutional investors and hedge funds have also modified their holdings of the company. DHJJ Financial Advisors Ltd. increased its stake in shares of Esperion Therapeutics by 209.2% in the third quarter. DHJJ Financial Advisors Ltd. now owns 9,430 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 6,380 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in Esperion Therapeutics during the second quarter valued at $25,000. Vanguard Personalized Indexing Management LLC acquired a new stake in Esperion Therapeutics during the third quarter valued at $29,000. R Squared Ltd purchased a new position in Esperion Therapeutics in the third quarter valued at about $33,000. Finally, CWM LLC increased its position in Esperion Therapeutics by 46.5% in the 3rd quarter. CWM LLC now owns 19,674 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 6,249 shares during the last quarter. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Benjamin Halladay sold 7,337 shares of the business’s stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $3.67, for a total transaction of $26,926.79. Following the transaction, the chief financial officer directly owned 467,525 shares in the company, valued at $1,715,816.75. The trade was a 1.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 15,543 shares of company stock worth $55,709 over the last 90 days. 1.70% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts have commented on the stock. Citizens Jmp boosted their target price on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “market outperform” rating in a research report on Friday. Piper Sandler started coverage on Esperion Therapeutics in a research report on Tuesday, November 25th. They issued an “overweight” rating and a $9.00 price target for the company. Wall Street Zen raised Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Thursday, January 22nd. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.60.

Esperion Therapeutics Stock Down 1.2%

ESPR opened at $2.44 on Friday. The stock’s 50 day moving average price is $3.28 and its two-hundred day moving average price is $3.14. The firm has a market capitalization of $626.62 million, a P/E ratio of -14.35, a price-to-earnings-growth ratio of 1.18 and a beta of 1.11. Esperion Therapeutics, Inc. has a 12-month low of $0.69 and a 12-month high of $4.18.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.01). The firm had revenue of $168.45 million during the quarter, compared to the consensus estimate of $165.12 million. As a group, analysts anticipate that Esperion Therapeutics, Inc. will post -0.29 earnings per share for the current year.

Esperion Therapeutics News Roundup

Here are the key news stories impacting Esperion Therapeutics this week:

• Positive Sentiment: Citizens Jmp raised its price target on ESPR to $5.00 (from $4.00) and assigned a “market outperform” rating — implying roughly 105% upside vs. the reference $2.44 level, which could attract buyers and trigger short‑covering. Article Title Article Title
• Neutral Sentiment: Street analysts published Q4 forecasts for ESPR; these refreshes create short‑term volatility but are routine ahead of reporting periods — watch actual Q4 results vs. the new consensus for a catalyst. Article Title
• Negative Sentiment: HC Wainwright lowered multi‑year EPS targets materially while maintaining a “Buy” rating: FY2026 cut to $0.00 (from $0.58), FY2027 to $0.25 (from $0.81) and FY2028 to $0.45 (from $1.07). The firm also models small quarterly losses (Q1 -$0.08, Q2 -$0.05, Q3 -$0.04) before the projected recovery — the revisions reduce future earnings power embedded in current valuations and likely weigh on the stock. Article Title

Esperion Therapeutics Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.